Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer

This study tests a combination chemotherapy regimen (irinotecan liposome, 5-FU, leucovorin, and oxaliplatin) given before and after surgery for people with borderline resectable pancreatic cancer — meaning the tumor is close to but not yet invading nearby blood vessels, making surgery possible but risky. **You may be eligible if...** - Your pancreatic cancer has been classified as borderline resectable by NCCN guidelines - You have not received any prior cancer treatment (chemotherapy, radiation, or surgery for cancer) - You have adequate organ function and an ECOG performance score of 0 or 1 - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have a rare non-ductal type of pancreatic cancer (neuroendocrine, acinar, or blastoma) - You have severe digestive problems - You have had a serious infection in the past 4 weeks - You have significant heart problems (heart failure, unstable angina, or recent heart attack) - You are allergic to any components of the regimen - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.